Swedish biotech Pila Pharma has announced an update to its preclinical obesity studies, concluding that the absence of an effect on body weight in rats was most likely caused by insufficient drug exposure rather than lack of efficacy. The company is now pressing ahead with clinical preparations.
Read the full article at biostock.se:
https://biostock.se/en/2026/04/pila-pharmas-prekliniska-resultat-forklaras-sannolikt-av-lag-lakemedelsexponering/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se